Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Merit Medical Systems, Inc. or Haemonetics Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Merit Medical Systems, Inc. and Haemonetics Corporation compare based on key financial metrics to determine which better meets your investment needs.

About Merit Medical Systems, Inc. and Haemonetics Corporation

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems. It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Latest Health Care Equipment & Supplies and Merit Medical Systems, Inc., Haemonetics Corporation Stock News

As of September 4, 2026, Merit Medical Systems, Inc. had a $5.4 billion market capitalization, compared to the Health Care Equipment & Supplies median of $423.0 million. Merit Medical Systems, Inc.’s stock is up 1.7% in 2026, down 1% in the previous five trading days and down 2.77% in the past year.

Currently, Merit Medical Systems, Inc.’s price-earnings ratio is 36.9. Merit Medical Systems, Inc.’s trailing 12-month revenue is $1.6 billion with a 9.2% net profit margin. Year-over-year quarterly sales growth most recently was 9.5%. Analysts expect adjusted earnings to reach $4.302 per share for the current fiscal year. Merit Medical Systems, Inc. does not currently pay a dividend.

As of September 4, 2026, Haemonetics Corporation had a $4.7 billion market cap, putting it in the 66th percentile of all stocks. Haemonetics Corporation’s stock is up 28.4% in 2026, down 1% in the previous five trading days and up 90.31% in the past year.

Currently, Haemonetics Corporation’s price-earnings ratio is 50.0. Haemonetics Corporation’s trailing 12-month revenue is $1.4 billion with a 7.1% net profit margin. Year-over-year quarterly sales growth most recently was 5.6%. Analysts expect adjusted earnings to reach $5.297 per share for the current fiscal year. Haemonetics Corporation does not currently pay a dividend.

How We Compare Merit Medical Systems, Inc. and Haemonetics Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Merit Medical Systems, Inc. and Haemonetics Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Merit Medical Systems, Inc. and Haemonetics Corporation’s Quality Grades

Company	Ticker	Quality
Merit Medical Systems, Inc.	MMSI	B
Haemonetics Corporation	HAE	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Merit Medical Systems, Inc. has a Quality Score of 80, which is Strong. Haemonetics Corporation has a Quality Score of 96, which is Very Strong.

The Quality Grade Winner: Haemonetics Corporation

As you can clearly see from the Quality Grade breakdown above, Haemonetics Corporation has a better overall quality grade than Merit Medical Systems, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Haemonetics Corporation could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Merit Medical Systems, Inc. and Haemonetics Corporation’s Momentum Grades

Company	Ticker	Momentum
Merit Medical Systems, Inc.	MMSI	B
Haemonetics Corporation	HAE	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Merit Medical Systems, Inc. has a Momentum Score of 65, which is Strong. Haemonetics Corporation has a Momentum Score of 91, which is Very Strong.

The Momentum Grade Winner: Haemonetics Corporation

As you can clearly see from the Momentum Grade breakdown above, Haemonetics Corporation is considered to have stronger momentum compared to Merit Medical Systems, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Haemonetics Corporation could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Merit Medical Systems, Inc. and Haemonetics Corporation’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Merit Medical Systems, Inc.	MMSI	B
Haemonetics Corporation	HAE	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Merit Medical Systems, Inc. has a Earnings Estimate Score of 75, which is Positive. Haemonetics Corporation has a Earnings Estimate Score of 57, which is Neutral.

The Earnings Estimate Revisions Grade Winner: Merit Medical Systems, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Merit Medical Systems, Inc. has a better Earnings Estimate Revisions Grade than Haemonetics Corporation. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Merit Medical Systems, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Merit Medical Systems, Inc. and Haemonetics Corporation Grades

In addition to Estimate Revisions, Momentum and Quality, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Merit Medical Systems, Inc. and Haemonetics Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Merit Medical Systems, Inc. or Haemonetics Corporation Stock?

Overall, Merit Medical Systems, Inc. stock has a Momentum Score of 65, Estimate Revisions Score of 75 and Quality Score of 80.

Haemonetics Corporation stock has a Momentum Score of 91, Estimate Revisions Score of 57 and Quality Score of 96.

Comparing Merit Medical Systems, Inc. and Haemonetics Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.